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ABSTRACT
Cross-reactivity in IgE epitopes and T cell epitopes has
been reported between major birch pollen allergen
(Bet v1) and major apple allergen (Mal d1). To treat
people with birch pollinosis complicated by apple
hypersensitivity by peptide immunotherapy, a sequential
IgE epitope analysis was performed to study IgE epi-
topes that recognize birch pollen and apple allergens
at the level of peptides. Subjects in the present study
were three patients who exhibited clinical symptoms
indicative of birch pollinosis during the pollen season.
Two of the three patients had apple hypersensitivity
and the capsulated hydrophobic carrier polymer (CAP)-
radioallergosorbent test (RAST) class for apple was at
least 2. The IgE epitope assay was performed by
peptide–CNBr gel binding assay. In two of the three
patients, IgE bound strongly to Bet vI 51–70 peptide
and also to 11–30, 21–40, 11–120, 111–130 and
141–159 peptides. In the other patient, IgE bound to
11–30, 61–80, 111–130 and 141–159 peptides in a
comparable manner. The IgE epitopes of Bet v1 and
Mal d1 were found in similar locations. The results of
sequential IgE epitope analyses on Bet v1 and Mal d1
revealed epitopes near the proximal regions of these
allergens. Thus, the three-dimensional structure of Mal
d1 is likely similar to that of Bet v1, which suggests that
peptide immunotherapy designed for birch pollen is
more than likely to be effective against apple allergy.
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INTRODUCTION
Birch pollinosis is a commonly occuring disease in 
northern Europe, North America and northern Japan
(Hokkaido). In addition, it has long been recognized that
people who are allergic to birch pollens are often allergic
to fruits, such as apples. There are two types of birch
pollen allergen: (i) the major allergen (Bet v1), which
reacts in approximately 90% of patients with birch polli-
nosis; and (ii) the minor allergen (Bet v2). Mal d1 is the
major apple allergen. Because the amino acid sequence
of Bet v1 and Mal d1 share 64% similarity, some studies
have identified this homology as the cause of common
allergenicity.1 Bet v2 is a type of protein called profirin,
which is found in every eukaryote. Given that there is
homology in its amino acid sequence among various
species, some researchers have suggested that profilin
may play a role in the common allergenicity for birch
pollen and apples.2 Cross-reactivity in IgE epitopes and
T cell epitopes has been reported between Bet v1 and
Mal d1.3,4 At present, it is generally accepted that both
Bet v1 and Mal d1 play an important role in common
allergenicity. In Europe and America, immunotherapy has
been attempted using extracted birch pollen allergens.
Although this type of immunotherapy has been shown to
be somewhat effective, it has not been widely accepted as
an established treatment for birch pollinosis due to asso-
ciated undesirable adverse reactions.5,6 Therefore, to
treat people with birch pollinosis complicated by apple
hypersensitivity by peptide immunotherapy, a sequential
IgE epitope analysis was performed to study IgE epitopes
that recognize birch pollen and apple allergens at the
level of peptides.
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METHODS
Subjects were three patients who exhibited clinical symp-
toms indicative of birch pollinosis during the pollen
season. In addition, eosinophils were detectable in 
the nasal discharge of these patients, and the capsulated
hydrophobic carrier polymer–radioallergosorbent test
(CAP-RAST; Pharmacia, Uppsala, Sweden) class for birch
pollens was at least 4. Two of the three patients had apple
hypersensitivity and the CAP-RAST class for apple was at
least 2. The human leukocyte antigen (HLA) haplotype of
the three patients was not examined.
Allergens were prepared as follows: ether-extracted
Betula platyphylla var. japonica pollen was used as whole
birch pollen extract and 1 g of this material was solubi-
lized in 10 mL of 20 mmol/L phosphate buffer at 4°C for
3 h. After centrifugation (12 000 g, 10 min), the super-
natant was ultrafiltrated with an ultrafiltration membrane
(YM1; Amicon, Beverly, MA, USA). Extracts of apple were
prepared by a low-temperature acetone powder method
described previously.7
Western blotting was performed as follows: crude 
allergens were extracted from birch pollens and apples,
and were subjected to 12% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE). Next,
allergens were transferred to a polyvinylidene difluoride
(PVDF) membrane (Millipore, Bedford, MA, USA) by semi-
dry blotting and the membrane was then treated with 3%
bovine serum albumin (BSA; Bio-Rad, Hercules, CA, USA),
patient serum (primary antibodies: diluted five-fold), and
[125I]-antihuman IgE antibodies (Pharmacia) as secondary
antibodies in this order and analyzed by autoradiography.
The CNBr-sepharose CL4B (Pharmacia) gel (1 mL)
and synthesized peptides (10 mg) were bound and, after
washing the resulting gel thoroughly, 0.2 mL of this gel
and 0.2 mL serum were allowed to react overnight. After
washing the gel–serum mixture, 0.2 mL [125I]-anti-IgE
antibody was added and the resulting gel–antibody
mixture was allowed to react for 5 h. The radioactivity
was then analyzed using a gamma counter.
The inhibition assay was perfomed as follows: serum
IgE- and gel-bound crude allergens were bound in the
presence or absence of 51–70 or 81–100 peptide. Each
peptide was used at final concentrations of 0.04, 0.2 and
1 mg/mL.
Peptides were prepared as follows: on the basis of the
amino acid sequence of Bet v1 and Mal d1, 20 amino
acid-long peptides were synthesized (overlap of 10 amino
acids). In addition, to bind peptides with gel, lysine was
added to the C-terminus of each peptide. The molecular
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Fig. 1 Western blotting was performed as follows: crude allergens were extracted from birch pollens and apples and were sub-
jected to 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Next, allergens were transferred to a polyvinylidene
difluoride (PVDF) membrane by semidry blotting and the membrane was then treated with 3% bovine serum albumin, patient serum,
[125I]-antihuman IgE antibodies in this order, and analyzed by autoradiography. Lane 1, molecular weight marker stained with
Coomassie brillant blue R-250 staining; lane 2, birch pollen (Betula platyphylla var. japonica); lane 3, serum from patient W; lane 4,
serum from patient Y; lane 5, serum from patient I; lane 6, serum from a healthy control; lane 7, apple extract; lane 8, pooled sera
from three patients.
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Fig. 2 CNBr-sepharose CL4B gel (1 mL) and synthesized peptides (10 mg) were bound and, after washing the resulting gel 
thoroughly, 0.2 mL of this gel and 0.2 mL serum were allowed to react overnight. After washing the gel–serum mixture, 0.2 mL 
[125I]-antihuman IgE antibody was added and the resulting gel–antibody mixture was allowed to react for 5 h and radioactivity was
then analyzed using a gamma counter.The reaction between patient serum and gel bound with rough allergens extracted from birch
pollens was defined as ‘1’ and the reaction of each peptide was expressed in relation to this reaction. AA no., amino acid number
from the N-terminus of the protein.
Fig. 3 The reaction between patient serum and gel bound with rough allergens extracted from apple extract was defined as ‘1’
and the reaction of each peptide was expressed in relation to this reaction. AA no., amino acid number from the N-terminus of the
protein.
weight of the synthesized peptides was confirmed by mass
spectrometry.
RESULTS
Western blotting
A band corresponding to Bet v1 was seen when the
serum sample of any of the three patients was allowed to
react with crude birch pollen allergens (Fig. 1). In addi-
tion, a band corresponding to Mal d1 was seen when the
pooled sera of the three patients was allowed to react
with crude apple allergens.
Bet v1-patient serum binding
The reaction between patient serum and gel bound 
with crude allergens extracted from birch pollens was
defined as ‘1’ and the reaction of each peptide 
was expressed in relation to this reaction. A reaction
was defined as positive when it was greater than the
mean ± 2.5 SD of the control serum or when the ratio
of the reaction to control serum was greater than 0.1. In
two of the three patients (patients W and Y), serum IgE
bound strongly to 51–70 peptide and also to 11–30,
21–40, 111–130 and 141–159 peptides. In the other
patient (patient I), serum IgE bound to 11–30, 61–80,
111–130 and 141–159 peptides in a comparable
manner (Fig. 2).
Mal d1-patient serum binding
In one patient, serum IgE bound to 11–30, 41–60, 51–70,
101–120, 111–130 and 141–159 peptides, while in the
other patient, serum IgE bound to 11–30, 51–70, 61–80,
91–110 and 141–159 peptides (Fig. 3).
51–70 peptide suppression test
Because the 51–70 peptide showed a high degree of
reactivity in two patients, we investigated whether the
reaction between serum and crude allergen gel could be
suppressed by 51–70 peptide (Fig. 4). Samples were
preincubated in the presence of 51–70 peptide or
81–100 peptide. The results show that, when compared
to 81–100 peptide, the degree of suppression was
stronger with 51–70 peptide.
Comparison of the location of sequential IgE
epitopes in Bet v1 and Mal d1
Figure 5a compares the sequential IgE epitopes of Bet v1
and Mal d1 (left-hand panel) and the concordance rate
of the amino acid sequence of Bet v1 and Mal d1 for
each peptide (right-hand panel). The IgE epitopes of Bet
v1 and Mal d1 were found in similar locations and the
homology of the amino acid composition of the epitopes
of the two allergens was relatively high.
DISCUSSION
In currently available peptide immunotherapy, a peptide
is designed by identifying the T cell epitope of an aller-
gen. However, T cell epitopes vary from one patient to the
next, depending on HLA type, and if it resembles the
major histocompatibility complex binding motif, most
areas of the protein can act as epitopes. Furthermore,
preparing a peptide that is applicable to different races
can be difficult. In contrast, in the case of an IgE epitope,
a target epitope is present on the surface of allergens and
is independent of HLA and, as such, it is easier to prepare
more specific peptides. Chemical mediators are released
when IgE on mast cells cross-links, but degranulation
does not occur with single-valency allergens. Hence, if
the entire sequence of Bet v1 is included with no more
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Fig. 4 51–70 peptide showed a high degree of reactivity in
two patients, so we investigated whether the reaction between
serum and rough allergen gel could be suppressed by 51–70
peptide. (), preincubation in the presence of 51–70 peptide;
(), preincubation in the presence of 81–100 peptide. The
results showed that, when compared with 81–100 peptide, the
degree of suppression was stronger with 51–70 peptide. PBS,
phosphate-buffered saline.
than one IgE epitope, then all T cell epitopes can be
included and therapy can be administered without induc-
ing anaphylactic shock. Therefore, in the present study,
sequential IgE epitope analysis was performed to study IgE
epitopes that recognize birch pollen and apple allergens at
the level of peptides. The results confirmed several sequen-
tial IgE epitopes, including 51–70 peptide. Because the
three-dimensional structure of Bet v1 has been clarified
recently,8 we attempted to locate 51–70 within the three-
dimensional structure of Bet v1. The 51–70 residues were
somewhat exposed on the protein surface and were spread
over the β3 and β4 regions. Therefore, based on its three-
dimensional structure, this area is likely to be an IgE
epitope. Amino acid homology between Bet v1 and Mal
d1 is relatively high at the 11–70 residues of Bet v1 and
that region includes the IgE epitope. The results of sequen-
tial IgE epitope analyses on Bet v1 and Mal d1 revealed
epitopes near the proximal regions of these allergens.
Thus, the three-dimensional structure of Mal d1 is likely
similar to that of Bet v1, which suggests that peptide
immunotherapy designed for birch pollen is more than
likely to be effective against apple allergy.
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Fig. 5 (a) The left-hand panel compares the sequential IgE epitopes of Bet v1 and Mal d1, while the right-hand panel shows the
concordance rate of the amino acid sequence of Bet v1 and Mal d1 for each peptide. The IgE epitopes of Bet v1 and Mal d1 were
found in similar locations and the homology of the amino acid composition of the epitopes of the two allergens was relatively high.
(b) The amino acid sequence of Bet v1a and Mal d1.
REFERENCES
1 Rohac M, Birkner T, Reimitzer I et al. The immunological
relationship of epitope on major tree pollen allergens.
Mol. Immunol. 1991; 28: 897–906.
2 Valenta R, Duchene M, Pettenburger K et al. Identification
of profilin as a novel pollen allergen; IgE autoreactivity in
sensitized individuals. Science 1991; 253: 557–60.
3 Ebner C, Birkner T, Valenta R et al. Common epitopes of
birch pollen and apple. Studies by western and northern
blot. J. Allergy Clin. Immunol. 1991; 88: 588–94.
4 Fritsch R, Bohle B, Vollmann U et al. Bet v 1, the major
birch pollen allergen, and Mal d1, the major apple aller-
gen, cross-react at the level of allergen-specific T helper
cells. J. Allergy Clin. Immunol. 1998; 102: 679–86.
5 Herrmann D, Henzgen M, Frank E, Rudeschko O, Jäger L.
Effect of hyposensitization for tree pollinosis on sassociated
apple allergy. J. Invest. Allergol. Clin. Immunol. 1995; 5:
259–67.sw
6 Asero R. Effects of birch pollen-specific immunotherapy on
apple allergy in birch pollen hypersensitive patients. Clin.
Exp. Allergy 1998; 28: 1368–73.
7 Vieths S, Schöning B, Petersen A et al. Characterization of
the 18 kDa apple allergen by two-dimensional immuno-
blotting and microsequencing. Int. Arch. Allergy Immunol.
1994; 104: 399–404.
8 Gajhede M, Osmark P, Flemming M et al. X-ray and NMR
structure of Bet v 1, the origin of birch pollen allergy. Nat.
Struct. Biol. 1996; 3: 1040–5.
62 M UEHARA ET AL.
